Read by QxMD icon Read


Cher-Rin Chong, Gao J Ong, John D Horowitz
Angina pectoris, or symptomatic myocardial ischaemia, reflects an impairment of coronary blood flow, and usually a deficiency of available myocardial energetics. Treatment options vary with the precise cause, which may vary with regards to the roles of increased myocardial oxygen demand versus reduced supply. Traditionally, organic nitrates, β-adrenoceptor antagonists, and non-dihydropyridine calcium antagonists were the only commonly used prophylactic anti-anginal agents. However, many patients failed to respond adequately to such therapy, and/or were unsuitable for their use...
October 6, 2016: Expert Opinion on Emerging Drugs
Georgia Kourlaba, George Gourzoulidis, George Andrikopoulos, Konstantinos Tsioufis, Alexandra Beletsi, Nikos Maniadakis
BACKGROUND: To evaluate the cost-effectiveness of trimetazidine (TMZ) as add-on therapy to standard-of-care (SoC) compared to SoC alone in patients with chronic stable angina who did not respond adequately to first line therapy with b-blockers, nitrates or calcium channel antagonists in Greece. METHODS: A Markov model with 3-month cycles and 1-year time horizon was developed to assess the comparators. The analysis was conducted from a third-party payer perspective...
September 27, 2016: BMC Health Services Research
Ning Ma, Jingyun Bai, Weihua Zhang, Hong Luo, Xin Zhang, Donghai Liu, Chenhui Qiao
Trimetazidine is a piperazine-derived metabolic agent, which exerts cell protective effects and has been reported to be efficient in the treatment of chronic stable angina pectoris. In addition, it has been shown to exert protection against acute myocardial infarction. The present study aimed to investigate whether trimetazidine protects against cardiac ischemia/reperfusion (I/R) injury, and to determine whether its curative effects are associated with microRNA (miRNA)‑21 expression, Akt, and the B‑cell lymphoma 2 (Bcl‑2)/Bcl‑2‑associated X protein (Bax) pathway...
September 26, 2016: Molecular Medicine Reports
Filomena S G Silva, Rui F Simões, Renata Couto, Paulo J Oliveira
BACKGROUND: Cardiovascular diseases (CVDs) are one of the main factors responsible for human morbidity and mortality. Since mitochondria play a critical role in the regulation of cardiac tissue homeostasis, this organelle is a critical target for the protective effects of several pharmaceuticals. Although specific mitochondria-targeted antioxidants and some pharmacological agents are described as potential cardioprotective agents, there are still a few effective mitochondrial therapies for the treatment of CVDs...
August 22, 2016: Current Pharmaceutical Design
Cian P McCarthy, Kieran V Mullins, David M Kerins
With evidence for efficacy in such diverse clinical settings such as stable coronary artery disease, reperfusion injury, and contrast-induced nephropathy, trimetazidine (TMZ) is novel among cardiovascular agents. In spite of this and almost half a century of clinical experience with the drug, it remains licensed only as an adjunct in the management of angina pectoris in patients who are inadequately controlled by or intolerant to first-line therapies. Although no single pharmacological mechanism has been hitherto universally accepted, TMZ is known to target deranged cellular energetics particularly in ischaemic myocardial tissue...
October 2016: European Heart Journal. Cardiovascular Pharmacotherapy
Asma Mahfoudh Boussaid, Rabi Selmi, Mohamed Bejaoui, Kaouther Hadj Ayed, Mohamed Amine Zaouali, Hassen Ben Abdennebi
BACKGROUND/AIM: The aim of this study was to compare the effects of single and repeated trimetazidine (TMZ) administration against warm hepatic ischemia/reperfusion (I/R) injury and to explore the possible mechanisms affected by TMZ. MATERIALS AND METHODS: Wistar rats were divided into 4 groups (n = 6). Sham: rats were subjected to dissection. I/R: rats were subjected to 60 min of partial hepatic ischemia followed by 24 h of reperfusion. TMZ1: Same as I/R group but rats were pretreated with a single dose of TMZ (10 mg/kg, intraperitoneal injection) 30 min before warm ischemia...
2016: Turkish Journal of Medical Sciences
Mayer Bassan
No abstract text is available yet for this article.
July 21, 2016: New England Journal of Medicine
Maria M Wanitschek, Jakob Dörler, Hannes F Alber
No abstract text is available yet for this article.
July 21, 2016: New England Journal of Medicine
E Magnus Ohman
No abstract text is available yet for this article.
July 21, 2016: New England Journal of Medicine
Hui Li, Fu-Yuan Liu, Xiao-Lan Li, Xiao-Mei Li, Lei Zhu
The aim of the study was to compare the clinical effects of carvedilol and trimetazidine for the treatment of alcoholic cardiomyopathy. A total of 60 patients diagnosed with alcoholic cardiomyopathy were enrolled in the study. The patients were randomly divided into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The patients in the control, carvedilol and trimetazidine groups were treated with conventional drugs, conventional drugs + carvedil and conventional drugs + trimetazidine respectively, for 12 weeks...
August 2016: Experimental and Therapeutic Medicine
Yongyong Li, Dewei Wang, Chunxiao Hu, Peng Zhang, Dongying Zhang, Shu Qin
BACKGROUND: Several lines of evidence support the clinical use of trimetazidine as an adjunctive therapy in cardioischemic patients. Therefore, we assessed here the efficacy and safety of adjunctive trimetazidine therapy in acute myocardial infarction (MI) patients by a systematic review and meta-analysis of the current literature. METHODS: PubMed, the Cochrane Library, and the China National Knowledge Infrastructure databases were searched for clinical studies comparing adjunctive trimetazidine therapy against placebo in adult acute MI patients...
July 15, 2016: Cardiology
Khalid I Amber, Najah R Hadi, Bashaer M Muhammad-Baqir, Dina A Jamil, Hayder A Al-Aubaidy
BACKGROUND: This study aims to investigate the inflammatory response in Novolimus bioresorbable coronary scaffold implantation after a course treatment with trimetazidine (35mg tablet/twice daily for 4days). METHODS: This was a randomized single blind study. Forty diabetic patients with critical coronary stenosis were subjected to elective coronary scaffold implantation in Al-Najaf Center for Cardiac Surgery and Trans-Catheter Therapy, Najaf, Iraq, between January and July 2015...
October 1, 2016: International Journal of Cardiology
Nagla A El-Sherbeeny, Ghalia M Attia
Nephrotoxicity is a dose-limiting side effect of cisplatin (CSP). The study investigated the possible protective role of trimetazidine (TMZ) against CSP-induced nephrotoxicity in rats. Rats were divided into four groups; control, TMZ, CSP, and CSP + TMZ. The CSP group showed significant deterioration in kidney function with structural changes in the form of interstitial hemorrhage, glomeruli shrinkage and peritublar capillary congestion, tubular cells vacuolation, pyknosis, shedding and necrosis, and inflammatory cell infiltrates, all indicating renal damage...
July 2016: Canadian Journal of Physiology and Pharmacology
Mehmet Yaman, Uğur Arslan, Hasan Ali Gümrükçüoğlu, Musa Şahin, Hakkı Şimşek, Serkan Akdağ
BACKGROUND AND OBJECTIVES: Studies reveal that the microvolt T wave alternans (MTWA) test has a high negative predictive value for arrhythmic mortality among patients with ischemic or non-ischemic cardiomyopathy. In this study, we investigate the effects of trimetazidine treatment on MTWA and several echocardiographic parameters in patients with stable coronary artery disease. SUBJECTS AND METHODS: One hundred patients (23 females, mean age 55.6±9.2 years) with stable ischemic heart disease were included in the study group...
May 2016: Korean Circulation Journal
Elisabetta Ferraro, Fabrizio Pin, Stefania Gorini, Laura Pontecorvo, Alberto Ferri, Vincenzo Mollace, Paola Costelli, Giuseppe Rosano
BACKGROUND: The loss of muscle mass (sarcopenia) and the associated reduced muscle strength are key limiting factors for elderly people's quality of life. Improving muscle performance does not necessarily correlate with increasing muscle mass. In fact, particularly in the elderly, the main explanation for muscle weakness is a reduction of muscle quality rather than a loss of muscle mass, and the main goal to be achieved is to increase muscle strength. The effectiveness of Trimetazidine (TMZ) in preventing muscle functional impairment during ageing was assessed in our laboratory...
September 2016: Journal of Cachexia, Sarcopenia and Muscle
Tolgar Lütfi Kumral, Güven Yıldırım, Güler Berkiten, Ziya Saltürk, Enes Ataç, Yavuz Atar, Yavuz Uyar
OBJECTIVES: To evaluate the efficacy of trimetazidine dihydrochloride as a treatment for chronic tinnitus. METHODS: A total of 97 chronic tinnitus patients were evaluated in this randomized, prospective, double-blind, placebo-controlled trial. After assessing for eligibility, 82 patients were randomly assigned into placebo or trimetazidine groups according to the medication. The trimetazidine group received 20×3 mg/day per oral trimetazidine dihydrochloride and the placebo group received 20×3 mg/day per oral placebo for 3 months...
September 2016: Clinical and Experimental Otorhinolaryngology
Giuseppe Ambrosio, Michel Komajda, Alessandro Mugelli, José Lopez-Sendón, Juan Tamargo, John Camm
In 2013 the European Society of Cardiology (ESC) released new guidelines on the management of stable coronary artery disease. These guidelines update and replace the previous ESC guidelines on the management of stable angina pectoris, issued in 2006. There are several new aspects in the 2013 ESC guidelines compared with the 2006 version. This opinion paper provides an in-depth interpretation of the ESC guidelines with regard to these issues, to help physicians in making evidence-based therapeutic choices in their routine clinical practice...
September 2016: European Journal of Preventive Cardiology
Arif Suner, Mustafa Cetin
OBJECTIVES: Coronary slow flow (CSF) is associated with an increased incidence of adverse cardiovascular events. Previous studies have shown increases in P wave dispersion, QT dispersion, and the Tp-e/QT ratio, and a prolonged Tp-e interval, as well as left ventricular diastolic dysfunction in patients with CSF. We aimed to examine the effect of trimetazidine (TMZ) on these arrhythmia predictors and diastolic function of the left ventricle. METHODS: Our study included 30 patients with CSF and 30 individuals with normal coronary arteries...
August 2016: Coronary Artery Disease
Lei Zhang, Wen-Yuan Ding, Zhi-Hao Wang, Meng-Xiong Tang, Feng Wang, Ya Li, Ming Zhong, Yun Zhang, Wei Zhang
BACKGROUND: Trimetazidine, as an anti-ischemic and antioxidant agent, has been demonstrated to have many cardioprotective effects. However, whether early administration of trimetazidine has an effect on diabetic cardiomyopathy and the mechanisms underlying the effect have not yet been elucidated. METHODS: We established a type 2 DCM rat model by high-fat diet and low-dose streptozotocin. Rats were separated into different groups: control, diabetes, and diabetes + trimetazidine (n = 6, each)...
2016: Journal of Translational Medicine
Gaetano Antonio Lanza, Filippo Crea
Pharmacologic treatment of myocardial ischemia in patients with chronic stable angina (CSA) is mainly based on heart rate lowering drugs and vasodilator agents. Other drugs are available, however, that act by some peculiar mechanism (ranolazine, trimetazidine) and may add potential anti-ischemic and anti-anginal effects to standard therapeutic mechanisms. While anti-ischemic agents are crucial for controlling angina symptoms and improving quality of life, whether myocardial ischemia portends an ominous prognosis and its suppression improves clinical outcome in CSA patients remain debated issues...
August 2016: Cardiovascular Drugs and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"